G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.
Courtney D. DiNardo,Guilin Tang,Naveen Pemmaraju,Sa A. Wang,Allison Pike,Guillermo Garcia-Manero,Jorge E. Cortes,Carlos E. Bueso-Ramos,Hagop M. Kantarjian +8 more
TL;DR: With prompt therapy and intensive supportive care first remissions are frequently attained, however, patients have a high risk of relapse, extramedullary disease, and poor long-term outcomes.
Journal ArticleDOI
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Sandip P. Patel,Guillermo Garcia-Manero,A. Ferrajoli,Stefan Faderl,Serge Verstovek,Hagop M. Kantarjian,Elihu H. Estey +6 more
Journal ArticleDOI
Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
Guillermo Garcia-Manero,Guillermo Montalban-Bravo,Koji Sasaki,Naval Daver,Elias J. Jabbour,Yesid Alvarado,Courtney D. DiNardo,Farhad Ravandi,Gautam Borthakur,Prithviraj Bose,Naveen Pemmaraju,Kiran Naqvi,Jorge E. Cortes,Tapan M. Kadia,Marina Konopleva,Caitlin R. Rausch,Yvonne Gasior,Hagop M. Kantarjian +17 more
TL;DR: A basket exploratory phase 2 trial of ICPI in MDS to determine the safety of Nivo or Ipi as single agents or in combination with AZA and preliminary results suggest double immune checkpoint inhibitor blockade with Ipi and Nivo in frontline setting, or in pts with HMA failure is associated with a tolerable profile.
Journal ArticleDOI
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics
Aziz Nazha,Hagop M. Kantarjian,Vijaya Raj Bhatt,Graciela M. Nogueras-Gonzalez,Jorge E. Cortes,Tapan M. Kadia,Guillermo Garcia-Manero,Lynne V. Abruzzo,Naval Daver,Naveen Pemmaraju,Alfonso Quintás-Cardama,Farhad Ravandi,Michael J. Keating,Gautam Borthakur +13 more
TL;DR: Among patients with CK-AML, MK was associated with poor outcomes and additional presence of C17 abns further worsens the outcome in these particularly poor-risk patients with AML.
Journal ArticleDOI
Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Ricardo H. Alvarez,Hagop M. Kantarjian,Guillermo Garcia-Manero,Zeev Estrov,Farhad Ravandi-Kashani,Srdan Verstovsek,Francis J. Giles,Susan O'Brien,Charles Koller,Stefan Faderl,Deborah A. Thomas,John Wright,Jorge E. Cortes +12 more
TL;DR: It is concluded that Z combined with Ida and ara-C induces a high rate of CR in AML, with increased incidence of diarrhea and hyperbilirrrubinemia.